Angle Share Discussion Threads

[miavoce] 21/11/2024 09:04

Wrong thread.

[toffeeman] 20/11/2024 14:33

Here is the ling to an interesting discussion on CTDNA - I found it depressing that CTCs weren't mentioned, but it was clear that CTDNA needs companion diagnostics.

But overall it shows how complex things are - so worth a watch methinks

hxxps://event.on24.com/eventRegistration/console/apollox/mainEvent?&eventid=4742237&sessionid=1&username=&partnerref=&format=fhvideo1&mobile=&flashsupportedmobiledevice=&helpcenter=&key=EDAF1005D9FCECC0645F79D2BC17605A&newConsole=true&nxChe=true&newTabCon=true&consoleEarEventConsole=false&consoleEarCloudApi=false&text_language_id=en&playerwidth=748&playerheight=526&eventuserid=719455186&contenttype=A&mediametricsessionid=618221852&mediametricid=6672718&usercd=719455186&mode=launch

BW

[ericthebrown] 20/11/2024 14:19

Angle @ 6th Annual Congress Liquid Biopsy Exhibition Nov 23rd - 25th

Astrazeneca, Thermo Fisher and many others there too:-

[bermudashorts] 20/11/2024 13:15

News from Recursion Pharmaceuticals today:-

'Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery.

The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform.

“I believe the combination of the incredible teams and platforms at Exscientia and Recursion position us as the leader of the AI-enabled drug discovery and development space,” said Chris Gibson, Ph.D., Co-Founder and CEO of Recursion

The combination of our platforms and people make us the company to beat,” said David Hallett, Ph.D., former CSO and Interim CEO of Exscientia and newly appointed Chief Scientific Officer at Recursion. “With our combined strength of real-world proprietary data and the models we’ve created – hypothesizing, testing and learning in a continuous loop – we're redefining the space by shrinking timelines and costs, identifying and optimizing lead candidates faster than traditional methods.”

Angle of course signed an agreement with Recursion back in September.

[boris cobaka] 20/11/2024 12:21

final day of the AACR event.
Will be interesting to see if we get any feedback.

[m_night10] 20/11/2024 08:23

#POLX next less than half the mcap of #AGL but a stronger cash position and higher revenues and growth.

POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.

Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval.

Massive takeover target and will be sold for 20p+ share price.

1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M.

APPROX 13P SHARE PRICE EQUIVALENT FOR POLX


2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M

APPROX 48P SHARE PRICE EQUIVALENT FOR POLX


3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million.

APPROX 22P SHARE PRICE EQUIVALENT FOR POLX

4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout

POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice.

[boris cobaka] 20/11/2024 07:58

wouldn't bank on it. Study target dates are notorious for slipping. Just to get the required participants can be quite tricky.

[seball] 20/11/2024 06:56

2 x news due in next 6 weeks

Astrazeneca assay

End of April we were told 6 Month development phase. Expecting an update imminently . This could rerate the share price. BUY

"Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE."

Artios phase 1 results due by end of 2024
The successful development of these DDR assays (high levels of both sensitivity and specificity were achieved) was technically challenging and a significant achievement. Artios will now utilise the two assays in a Phase 1 clinical trial scheduled to begin shortly and expected to complete around the end of 2024. ANGLE anticipates that these assays could be employed in larger, later stage clinical trials for the same compound and potentially in further trials for additional compounds in the customer's pipeline.

[muffster] 19/11/2024 16:57

Probably is Bones

[kryptonsnake] 19/11/2024 15:54

Did I mention 30p by Christmas?



sent from my iPhone

[seball] 19/11/2024 15:53

Astrazeneca assay

End of April we were told 6 Month development phase. Expecting an update imminently . This could rerate the share price. BUY

"Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE."

Artios phase 1 results due by end of 2024
The successful development of these DDR assays (high levels of both sensitivity and specificity were achieved) was technically challenging and a significant achievement. Artios will now utilise the two assays in a Phase 1 clinical trial scheduled to begin shortly and expected to complete around the end of 2024. ANGLE anticipates that these assays could be employed in larger, later stage clinical trials for the same compound and potentially in further trials for additional compounds in the customer's pipeline.

[puphead] 19/11/2024 14:24

"Porsartix" - oh dear....

[bobbie121] 19/11/2024 12:01

“For research only, not for diagnostic purposes” Why does this still appear on so many of Angles slides used in presentations?

[pwhite73] 19/11/2024 10:29

fhmktg - "All will be revealed in the next couple of months."

Everything with AGL will always be revealed in the next couple of months never today.

Porsartix received FDA clearance on 25/05/2022 that's two and half years ago and they're still hogging around pharma conferences. Everybody knows what it can do diagnostically but does it have any real commercial value?.

[atmysignal] 19/11/2024 09:50

Will be back up soon.News dueIgnore the deramper30p

[moontheloon] 19/11/2024 09:09

It's just pure desperation from mnight in the continued absence of commercial news